• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Sonde Health Nabs $16M to Commercialize Vocal Biomarker Device to Diagnose Diseases

by Fred Pennic 04/12/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Sonde Health Nabs $16M to Commercialize Vocal Biomarker Device to Diagnose Diseases

Sonde Health, a Boston-based digital medicine company developing a vocal biomarker device to transform the way we monitor and diagnose our mental and physical health has raised $16 million in Series A funding. The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), with participation from MP Healthcare Venture Management, Inc. (the corporate venture capital arm of Mitsubishi Tanabe Pharma Corporation), Neoteny 4, LP, Canepa Healthcare, and founder PureTech Health. The Series A round includes issuance of $6 million in shares upon conversion of debt into equity.

Sonde Health’s Vocal Biomarker to Monitor and Diagnose Mental and Physical Health

Co-founded by PureTech Health, Sonde Health is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. Sonde’s proprietary technology is designed to enable a range of consumer devices, such as smartphones and smart speakers, to provide disease screening and management solutions based on acoustic analysis of seconds of voice.

Sonde is working to create seamless universal access to accurate and timely health information, which has the potential to promote wellness and improve the timing and selection of a range of therapeutic interventions. This approach may enable the prevention and treatment of conditions ranging from depression and respiratory diseases to chronic diseases of aging.

Traction/Milestones

To date, Sonde has collected voice and health data from over 10,000 subjects as part of the ongoing validation of its platform. These research and development data and activities are being accelerated to expand its proprietary technology into neurological, respiratory, and cardiovascular diseases as well as other health and wellness conditions. Sonde’s vocal biomarker program has demonstrated the potential to effectively screen and monitor for disease using information obtained from an individual’s voice on commonly-owned devices and it has the potential to fundamentally change the way mental and physical health is monitored and diagnosed.

Future Plans for Sonde

Sonde plans to use the proceeds from the Series A funding round to expand its capability across multiple health conditions and device types and to fund commercialization activities. “One of the oldest tools in our health care arsenal, the thermometer, is arguably still one of the most valuable because of its simplicity and widespread availability outside the clinical setting. Our longstanding vision has been to harness the health information present in billions of daily voice interactions to create a 21st century thermometer, or ‘vocometer’, that provides broad digital healthcare decision support needed to enable new models of precision and preventative medicine,” said Jim Harper, co-founder and chief operating officer of Sonde Health. “This financing round and the support of our new long-term partners allows us to accelerate the development of this groundbreaking technology and help deliver the positive impact it can have on an individual’s health and the healthcare system.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biomarkers, corporate venture capital, decision support, Depression, Digital Healthcare, Digital medicine, Partners, Pharma, Sonde Health, venture capital, Voice Recognition

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |